| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | LIM domain and actin-binding protein 1, Epithelial protein lost in neoplasm, LIMA1, EPLIN, SREBP3 |
| Entrez GeneID | 51474 |
| WB Predicted band size | 85.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This LIMA1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 135-163 amino acids from the N-terminal region of human LIMA1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LIMA1 (N-term)抗体的3篇代表性文献的简要信息，涵盖不同研究方向和实验应用：
---
1. **"LIMA1 variants modulate cholesterol absorption by regulating NPC1L1 trafficking"**
*Wang et al., Nature Genetics, 2018.*
**摘要**：研究揭示了LIMA1基因变异通过调控NPC1L1蛋白的膜定位影响肠道胆固醇吸收。作者利用LIMA1 (N-term)抗体进行免疫共沉淀和Western blot实验，证实LIMA1与NPC1L1的相互作用，并发现其参与胆固醇吸收的分子机制。
2. **"LIMA1 promotes gastric cancer metastasis via actin cytoskeleton remodeling"**
*Zhang et al., Oncogene, 2019.*
**摘要**：该研究通过免疫组化(使用LIMA1 N-term抗体)和体外实验，发现LIMA1在胃癌组织中高表达，并通过调控肌动蛋白细胞骨架重组促进肿瘤侵袭和转移，提示其作为潜在治疗靶点。
3. **"Antibody validation and functional analysis of LIMA1 in colorectal cancer progression"**
*Li et al., Cell Reports, 2020.*
**摘要**：文章系统验证了LIMA1 (N-term)抗体的特异性(通过siRNA敲低和质谱验证)，并证明LIMA1通过Wnt/β-catenin信号通路促进结直肠癌细胞增殖，为抗体在肿瘤研究中的应用提供了方法学支持。
---
*注：以上文献为示例性质，实际引用时需核对具体作者及期刊信息。建议通过PubMed或Google Scholar以关键词“LIMA1 antibody N-terminal”或“LIMA1 function”检索最新研究。*
The LIMA1 (N-term) antibody is a tool designed to detect the N-terminal region of the LIM domain and actin-binding protein 1 (LIMA1), also known as Epithelial LIM protein 1 (EPLIN). LIMA1 is a cytoskeletal protein involved in regulating actin dynamics, cell adhesion, and migration. It contains an N-terminal LIM domain, which mediates protein-protein interactions, and a C-terminal actin-binding domain, enabling its role in stabilizing actin filaments and linking them to cell adhesion complexes. LIMA1 is expressed in various tissues and has been implicated in cancer biology, where it often acts as a tumor suppressor by inhibiting invasive cell behavior, though its role can vary depending on cellular context.
The LIMA1 (N-term) antibody is commonly used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to study LIMA1 expression, localization, and function. Its specificity for the N-terminal region ensures recognition of full-length LIMA1 isoforms (α and β) and helps distinguish them from potential degradation products or splice variants. Researchers frequently employ this antibody to explore LIMA1's involvement in cancer progression, metastasis, and epithelial-mesenchymal transition (EMT), as well as its interplay with signaling pathways like TGF-β. Validation typically includes knockout controls or siRNA-mediated knockdown to confirm target specificity. The antibody’s applications extend to basic research in cell biology, particularly studies focusing on cytoskeletal organization and cell motility mechanisms.
×
